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Abstract
Background: We previously reported that the USP17 deubiquitinating enzyme having hyaluronan binding motifs (HABMs)
interacts with human SDS3 (suppressor of defective silencing 3) and specifically deubiquitinates Lys-63 branched
polyubiquitination of SDS3 resulting in negative regulation of histone deacetylase (HDAC) activity in cancer cells.
Furthermore, USP17 and SDS3 mutually interact with each other to block cell proliferation in HeLa cells but the mechanism
for this inhibition in cell proliferation is not known. We wished to investigate whether the HABMs of USP17 were responsible
for tumor suppression activity.
Methodology/Principal Findings: Similarly to USP17, we have identified that SDS3 also has three consecutive HABMs and
shows direct binding with hyaluronan (HA) using cetylpyridinium chloride (CPC) assay. Additionally, HA oligosaccharides (6-
18 sugar units) competitively block binding of endogenous HA polymer to HA binding proteins. Thus, administration of HA
oligosaccharides antagonizes the interaction between HA and USP17 or SDS3. Interestingly, HABMs deleted USP17 showed
lesser interaction with SDS3 but retain its deubiquitinating activity towards SDS3. The deletion of HABMs of USP17 could
not alter its functional regulation on SDS3-associated HDAC activity. Furthermore, to explore whether HABMs in USP17 and
SDS3 are responsible for the inhibition of cell proliferation, we investigated the effect of USP17 and SDS3-lacking HABMs on
cell proliferation by soft agar, apoptosis, cell migration and cell proliferation assays.
Conclusions: Our results have demonstrated that these HABMs in USP17 and its substrate SDS3 are mainly involved in the
inhibition of anchorage-independent tumor growth.
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Introduction
The homeostasis of a number of cellular proteins is regulated by
many molecular events that help to define the status and fate of
physiological processes. Such regulatory events include phosphor-
ylation, dephosphorylation, acetylation, deacetylation, and ubiqui-
tination. The process of ubiquitination is a well-established event
involving a complex yet organized milieu of ubiquitin-activating
enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin
ligase (E3) enzymes [1,2,3,4]. Deubiquitinating enzymes (DUBs)
are a large family of proteases, which counterbalance the
ubiquitination process by removing ubiquitin molecules from its
substrates [3,5,6]. Most DUBs are cysteine proteases and consist of
five known families: the ubiquitin C-terminal hydrolases (UCH),
the ubiquitin-specific processing proteases (USP), Jab1/Pab1/
MPN-domain containing metallo-enzymes (JAMM), Otu-domain
ubiquitin aldehyde-binding proteins (OTU), and Ataxin-3/Jose-
phin [3,4,7].
USP17 was previously identified as a human orthologue DUB-
3 that is regulated by IL-4 and IL-6 cytokines [8]. Several
evidences have proved that USP17 acts as a key regulator of cell
proliferation and survival [8,9,10,11]. More recently, chemokine
regulation of USP17 has been noticed in both elongated and
amoeboid cell motility. Depletion of endogenous expression of
USP17 inhibits normal cytoskeletal rearrangements and chemo-
kine-induced membrane localization of Rho GTPases [12]. In a
previous study, we showed that USP17 possesses two hyaluronan
binding motifs (HABMs) in its C-terminus region and interacts
with hyaluronan (HA) to regulate cell viability [13]. These
HABMs are termed B-X7-B motifs, where B refers to two flanking
basic amino acid residues (either arginine or lysine) and X is a non-
acidic amino acid [14]. However, the biological significance of
these HABMs in USP17 is not yet fully understood. In a recent
study, we reported that USP17 specifically deubiquitinates K63-
linked ubiquitination of SDS3 and negatively regulates SDS3-
associated HDAC activity in cancer cells [11].
HA is a negatively charged natural polysaccharide with a high
molecular weight, and is a common component of synovial fluid
and extracellular matrix. HA is responsible for various functions
within the extracellular matrix such as cell growth, adhesion,
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tasis and invasion [15,16]. In addition to its role in the
extracellular matrix, several evidences have proved that HA is
also present in the rough endoplasmic reticulum (ER) membranes,
plasma membranes, cytoplasm and nuclei of cells in a number of
tissues in vivo [17,18,19,20]. Several intracellular HA-binding
proteins have been reported to be involved in the regulation of cell
cycle or gene transcription [21,22,23,24,25,26]. Additionally, an
intracellular form of the HA receptor, RHAMM, has been shown
to be responsible for regulating extracellular-regulated kinase
activity [24]. HA is found to accumulate intracellularly in the
perinuclear region of aortic smooth muscle cells during premitotic
and mitotic stages [27]. This HA is found to aggregate at the
mitotic spindle and facilitate the process of nuclei separation and
subsequent cell division [20]. HA is closely associated with the
nuclei forming a cable structure that extends beyond the original
location of the cell membranes, suggesting that these HA cables
are initiated either by perinuclear or ER membranes [20]. The
accumulation of HA cables is elevated during ER stress in smooth
muscle cells [28]. In addition, HA cables serve as a distress signal
during inflammatory stimulus leading to monocyte activation and
also are capable of binding to leukocytes [28]. However, several
functions of intracellular HA are predicted during various cellular
processes, and the source of these intracellular HAs is not clearly
understood yet.
Perturbation of endogenous HA interaction in tumor cells
inhibits tumor growth, invasion and metastasis [29,30,31,32,33].
In addition, HA oligosaccharides have been shown to inhibit
tumor growth and induce apoptosis. Additionally, a synthetic
peptide containing at least three HABMs showed reduced tumor
growth and induced apoptosis [34,35]. HA oligosaccharides
competitively block binding of endogenous HA polymer to
CD44, consequently giving rise to attenuated signaling. HA
oligosaccharides also induce apoptosis and stimulate caspase-3
activity under anchorage-independent conditions [36], which was
similar to the action of USP17-containing HABMs transfected into
cervical adenocarcinoma cells causing apoptosis [11,13]. Thus,
elucidating the role of HABMs in USP17 on cell proliferation and
its implications on regulation of apoptosis in tumor cells is highly
desired.
Results and Discussion
Hyaluronan-binding Properties of USP17
HA is enriched in pericellular matrices surrounding proliferat-
ing and migrating cells. Elevated HA biosynthesis is a common
feature in many types of human cancers, and its constitutive
interaction with tumor cells has a major influence on tumor
growth and metastasis, promoting anchorage-independent growth
and invasiveness in animal models [37,38]. In a previous study, we
showed that USP17 possesses two HABMs [HABM1 (RRATQ-
GELKR) and HABM2 (KTKPEFNVR)] in its C-terminal region
that is located at amino acids 401 to 410, and 445 to 453,
respectively [13]. To find out which HABM is critical for HA-
binding of USP17, we generated a combination of HABM-
deletion constructs of USP17 for further investigation (Figure 1A).
We examined the HA-binding properties of USP17 by using
cetylpyridinium chloride (CPC) to specifically precipitate glycos-
aminoglycans. CPC is a cationic detergent that has a tendency to
bind and precipitate anionic glycosaminoglycans resulting in co-
precipitation of binding partners [39]. Thus, the CPC precipita-
tion assay showed that the deletion of the second HABM results in
a significant reduction of HA binding (Figure 1B, lane 4), and
both HABM-deletion constructs showed a marked reduction in
HA binding (Figure 1B, lane 5).
HA oligosaccharides inhibit growth of several types of tumors in
vivo [40]. These HA oligosaccharides competitively block binding of
endogenous HA polymer to HA-binding proteins [41]. Therefore,
we wished to investigate the effect of HA oligosaccharides on HA-
binding of USP17. To investigate whether HA oligosaccharides
bind with USP17, we examined the minimum concentration of HA
oligosaccharides required to precipitate USP17 using the CPC
assay.DuetothesmallsizeofHAoligosaccharides,itwasunlikelyto
observe any precipitation using the CPC assay, but with a high
amount of HA oligosaccharides ranging between 1000 and
2000 mg/ml, precipitation of USP17 could be detected
(Figure1C). Incontrast,thesamehighamountofoligosaccharides
(2000 mg/ml) could not precipitate both HABMs deleted USP17
(Figure 1D, lane 4), indicating the specific binding between
USP17 and HA oligosaccharides. Thus, our result shows that HA
oligosaccharides have binding capacity for USP17. We next
examined the ability of HA oligosaccharides to antagonize the
interaction between USP17 and HA. Interestingly, we observed a
significant reduction in USP17 binding with polymeric HA in the
presence of HA oligosaccharides compared to that inthe absence of
HA oligosaccharides (Figure 1B, lane 7). As a negative control,
distilled water was added instead of HA (Figure 1B, lane 8). This
result signifies that HA oligosaccharides show antagonistic effect on
USP17 binding with polymeric HA. In order to address the
specificity of HABMs, we synthesized the peptides mimicking
HABMs of USP17 and performed CPC assay (Figure 1E). The
blocking effect of peptides on the interaction between HA and
USP17 was shown even though it was not as strong as HA
oligosaccharides(Figure1E,lanes3-5).Thus,ourresultindicates
thatHAoligosaccharideshavespecificbindingcapacityforHABMs
of USP17.
SDS3 Binds with HA
Mouse SDS3 (mSDS3) is a key component of the mSin3-HDAC
complex, sharing physical and functional properties of its yeast
ortholog and shares 99.6% identity with human SDS3. The
impact of mSDS3 haploinsufficiency on cancer development along
with p53-dependent checkpoint control reveals that loss of one
mSDS3 allele accelerates tumor onset and increased tumor burden
in p53 null background [42,43].
In a recent study, human SDS3 was identified as a potential
binding partner for USP17 by MALDI-TOF analysis [11]. The
functional interaction between USP17 and SDS3 was responsible
for inducing apoptosis through negative regulation of HDAC
activity. Thus, USP17 and SDS3 mutually interact with each other
to affect cell viability of cancer cells. The fact that SDS3 alone has
an inhibitory effect on cell proliferation led us to speculate that
SDS3 may also have some motifs within its sequence that are
responsible for blocking cell proliferation. An examination of the
deduced amino acid sequence of SDS3 revealed three consecutive
overlapping HABMs (301-KTSDSTKMRIYLGQLQRGLF-
VIRRR-325) in its C-terminus (Figure 2A). More interestingly,
it has been reported that a synthetic peptide having at least three
HABMs showed reduced tumor growth and induced apoptosis
[35]. Later, it has been shown that a 42-amino acid peptide
(designated as BH-P) containing several HABMs from human
brain HA-binding protein inhibits tumor growth and induces
apoptosis [34]. These results indicate that the HABMs are
responsible for the anti-tumor effect. We compared and aligned
the amino acid sequences of the HA-binding regions of SDS3 to
synthetic peptide BH-P (Figure 2B). We investigated whether
SDS3 binds to HA, by performing the CPC assay. As a positive
Mapping of HABM Sites in USP17 and SDS3
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CPC assay. SDS3 was readily detected in the CPC precipitates
after preincubation with exogenous HA, in contrast to water, which
was taken as a negative control (Figure 2C). Next, we wished to
examine whether the HA binding ability of SDS3 was acquired due
to its interaction with USP17. For this purpose, we investigated the
HA binding ability of SDS3 in the presence of depletion of
endogenous USP17. Our result suggests that SDS3 binds to HA
and is independent to its interaction with USP17 (Figure 2C lane
4). To investigate the direct interaction between HA and USP17 or
SDS3, we incubated purified His-tagged SDS3 and GST-tagged
USP17 proteins separately with polymeric HA and performed the
CPC assay (Figure 2D). The CPC precipitation assay showed that
USP17 and SDS3 directly bind with HA.
Hyaluronan-binding Properties of SDS3
Identification of three consecutive HABMs in SDS3 led us to
validate HA-binding properties of SDS3 by deleting three
consecutive HABMs (301-KTSDSTKMRIYLGQLQRGLF-
VIRRR-325) and we analyzed the HA-binding ability of SDS3
by CPC assay. From CPC assay, we found that the HA-binding
ability of SDS3 was greatly reduced in the absence of the HABMs
(Figure 3, lane 3). These results suggest that the HABMs are
critical for HA-binding of SDS3. We further confirmed the
binding tendency of SDS3 with HA oligosaccharides at different
concentrations and found precipitation of SDS3 only at a high
concentration (Figure 3, lane 5). The effect of HA oligosaccha-
rides at a concentration of 500 mg/ml showed an antagonistic
Figure 1. Hyaluronan-binding activity of USP17. A) Schematic representation of HABM-deleted constructs of USP17. B) HA binding to HABM-
deleted constructs of USP17. Cell lysate aliquots from 293 T cells transfected with different USP17 deletion constructs were incubated with HA and
HA oligosaccharides and subjected to CPC precipitation. Western blot analysis was performed using an anti-myc antibody. The lower panel contains
an aliquot of whole cell lysate without addition of CPC or HA. C) Binding of USP17 to HA oligosaccharides. Cell lysate aliquots from 293 T cells
transfected with USP17 were incubated with different concentration of HA oligosaccharides and subjected to CPC precipitation followed by Western
blot analysis with an anti-myc antibody. D) Cell lysate aliquots from 293 T cells transfected with USP17 and HABMs-deleted USP17 were incubated
with high concentration of HA oligosaccharides (2000 mg) and performed CPC precipitation followed by Western blot analysis. E) Cell lysate aliquots
from 293 T cells transfected with USP17 were incubated with 20 mg of each USP17 peptide or together in the presence of HA and performed CPC
precipitation followed by Western blot analysis.
doi:10.1371/journal.pone.0037772.g001
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Overall, the data indicate that the interaction between polymeric
HA and SDS3 was competitively inhibited by low molecular
weight HA oligosaccharides, suggesting that HABMs in SDS3 are
essential for HA-binding and imply a distinct HA-binding region
on SDS3.
HABM-deletion Construct of USP17 has Less Binding
Affinity for SDS3 but Retain its Catalytic Activity on SDS3
Protein
We inquired whether deletion of HABMs from USP17 affects
its interaction and deubiquitinating activity on SDS3. We
therefore conducted a binding assay between HABM- deletion
construct of USP17 and SDS3. Interestingly, HABM-deletion
construct of USP17 showed significantly lesser interaction with
SDS3 when compared with the full length USP17 (Figure 4A,
lanes 6 and 7). In addition, HABM-deletion construct of USP17
and HABM-deletion construct of SDS3 showed weaker interac-
tion (Figure 4A, lane 8). Furthermore, we investigated the
interaction between SDS3 and first HABM deleted USP17 or
second HABM deleted USP17. The result showed that the second
HABM deleted USP17 has weak binding intensity than the first
HABM deleted USP17 with the full length SDS3 (Figure 4B).
However, the overlapped arrangement of HABMs within SDS3
was difficult in characterizing the binding intensity of each HABM
of SDS3 with the full length USP17.
Then, we wished to investigate the deubiquitinating activity of
HABM-deletion construct of USP17 on SDS3. The HABM-
deletion construct of USP17 could deubiquitinate SDS3 which was
similar to the activity of the full length USP17 (Figure 4C, lanes
4 and 5). Thus, the deletion of HABMs from USP17 did not
disrupt the catalytic activity of USP17 which is essential for
deubiquitination of SDS3 protein. These results suggest that
HABMs in USP17 contribute to the interaction between USP17
and SDS3, but do not affect the deubiquitinating activity of
USP17 on SDS3.
Figure 2. Binding of SDS3 to HA. A) Identification of three overlapping HABMs in SDS3 nucleotide and deduced amino acid sequence. HABMs are
represented in bold face and underlined (301-325 aa). B) Comparison and alignment of SDS3 amino acid sequence and BH-P. C) SDS3 binds with HA.
CPC precipitation assay was performed on 293 T cells transfected with USP17, SDS3 and SDS3/USP17-shRNA. Proteins precipitated with HA were
subjected to Western blot analysis with either an anti-myc or an anti-Flag antibody. D) USP17 and SDS3 directly bind with HA. CPC precipitation assay
was performed on purified GST-tagged USP17 or His-tagged SDS3 proteins separately. Western blot analysis with either an anti-GST or an anti-His
antibody was performed.
doi:10.1371/journal.pone.0037772.g002
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Proliferation
We hypothesized that the deletion of HABMs from USP17
showing reduced interaction with SDS3 could be involved in the
regulation of cell proliferation. For this purpose, we investigated
whether USP17 and SDS3-containing HABMs have an inhibitory
effect on anchorage- independent growth of tumor cells. Mock
control HeLa cells displayed large number of colonies, while HeLa
cells transfected with USP17 alone showed a greater reduction in
colony formation (Figure 5A). In contrast, USP17DHABM1 and
USP17DHABM2 showed lesser inhibitory effect than USP17. In
addition, HeLa cells transfected with USP17 lacking both the
HABMs showed a significantly large number and size of colonies
which was similar to the mock control. Interestingly, the growth
inhibiting effect of USP17 was not altered in the presence of
depletion of endogenous SDS3 (Figure 5A). Scrambled shRNA
(Mock-shRNA) which lacks sequence homology to the genome
was used as a control in our studies showed no effect on USP17-
mediated cell proliferation (Figure 5A). The knockdown efficien-
cy of SDS3-shRNA1 and shRNA2 was analyzed by Western
blotting (Figure 5B). Similarly, SDS3-transfected cells signifi-
cantly reduced the size and number of colonies formed on soft
agar when compared to the mock control. In contrast,
SDS3DHABMs-transfected cells showed significant increase in
colony formation (Figure 5C). Interestingly, the growth inhibiting
effect of SDS3 was not changed by the depletion of endogenous
USP17 (Figure 5C). The knockdown efficiency of USP17-
shRNA1 and shRNA2 was checked by Western blot analysis in
HeLa cells (Figure 5D). Same experiments were repeated in
MCF-7 cells and obtained similar results (data not shown).
Further, we demonstrated the inhibitory effect of USP17 and
SDS3, and its HABM-deletion constructs on cell growth using soft
agar assay. Mock control HeLa cells displayed a large number of
colonies, while HeLa cells transfected with USP17 or SDS3 alone
showed a greater reduction in colony formation. In addition,
USP17 and SDS3 co-transfected cells significantly reduced the size
and number of colonies formed on soft agar and exhibited about
75% reduced cell proliferation when compared to a mock control
(Figure 5E). In contrast, co-transfection of USP17 and SDS3-
lacking HABMs showed a significantly lesser inhibitory effect on
cell growth. To cross confirm this effect, we performed a cell
proliferation assay using a Cell Counting kit-8 for over 72 hrs in
three separate experiments. The co-transfection of HABM-
deletion construct of USP17 and HABM-deletion construct of
SDS3 showed lesser inhibitory effect on cell proliferation when
compared with the effect observed in USP17 and SDS3 co-
transfected cells (Figure 5F). The FACS analysis of the propidium
iodide (PI) and annexin V stained cells showed about 5 fold
increase in early stage of apoptosis in USP17 and SDS3 co-
transfected cells, while cells co-transfected with HABM-deleted
USP17 and SDS3 did not show any significant level of apoptosis
when compared with a mock control (Figure 5G). To further
evaluate the effect of HABMs of USP17 and SDS3 on cell
Figure 3. Hyaluronan binding activity of SDS3. Cell lysate aliquots from 293 T cells transfected with SDS3 and HABM-deleted construct of SDS3
were incubated with HA and different concentration of HA oligosaccharides, and subjected to CPC precipitation followed by Western blot analysis
with an anti-Flag antibody.
doi:10.1371/journal.pone.0037772.g003
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tion of USP17 and SDS3 showed significant reduction in cell
migration when compared with the HABMs deleted USP17 and
SDS3 (Figures 5H). Thus, the co-transfection of USP17 and
SDS3 showed combined effect of tumor growth suppression.
Altogether, our result indicates that the growth inhibiting action of
USP17 and SDS3 is not mainly regulated by its interaction but
due to the presence of HABMs in its sequence.
Furthermore, we hypothesized that the HABMs deleted USP17
retaining the deubiquitinating activity on SDS3 is independent of
its tumor growth suppressing activity. For this purpose, we
investigated HDAC assay on anti-SDS3 immunoprecipitates in
three independent experiments. HeLa cells transfected with empty
vector, SDS3, USP17/SDS3, USP17DHABM1/SDS3, USP17D-
HABM2/SDS3, USP17DHABMs/SDS3, USP17-shRNA1/
SDS3, USP17-shRNA2/SDS3 and Mock-shRNA/SDS3 were
subjected to immunoprecipitation using an anti-SDS3 antibody
and HDAC assay was performed. Overexpression of USP17,
USP17DHABM1, USP17DHABM2 and USP17DHABMs
showed similar SDS3-associated HDAC activity, while the
depletion in endogenous expression of USP17 increased the
SDS3-associated HDAC activity (Figure 6). Thus, our result
indicates that deubiquitinating activity of USP17, USP17D-
HABM1, USP17DHABM2 and USP17DHABMs showed similar
regulation on SDS3-associated HDAC activity.
In this study, we identified and characterized HABMs in
USP17 and SDS3 showing HA-binding affinity. Furthermore,
we provide evidence for a functional interaction between USP17
and SDS3-containing HABMs, which plays a crucial role in
regulating cell viability. Deletion of HABMs from USP17 and
SDS3 attenuated its inhibitory effect on cell proliferation but
could not affect its deubiquitinating activity and its functional
regulation on SDS3-associated HDAC activity. Taken together,
our data suggest that the HA-binding activity of USP17 may
contribute to the growth suppressing activity to balance the
action between ubiquitination and deubiquitination to ensure
the cellular homeostasis.
Materials and Methods
Construction of Expression Vectors
The cDNAs encoding the full length USP17 in pcDNA3.1
expression vector, full length SDS3 in pCS4-Flag expression
vector, GST-tagged USP17, His-tagged SDS3, USP17-shRNA1,
USP17-shRNA2, SDS3-shRNA1, and SDS3-shRNA2 in pSilen-
cer vectors have been previously described [11]. The word
‘‘Mock’’ in the gene silencing figures refers to a control with a
scrambled shRNA sequence. HABM-deletion constructs of USP17
and SDS3 were created by a method for site-directed mutagenesis.
USP17DHABM1, USP17DHABM2, and USP17DHABMs were
cloned into the pcDNA3.1 vector. SDS3DHABMs was subcloned
into the pCS4-Flag vector.
Figure 4. HABMs deleted USP17 deubiquitinates SDS3. A) Interaction between HABMs deleted USP17 and SDS3. B) Interaction between
USP17DHABM1 or USP17DHABM2 and SDS3. Interaction was confirmed by co-immunoprecipitation with either an anti-myc antibody or an anti-Flag
antibody. C) Deubiquitination of SDS3 by HABMs deleted USP17. 293 T cells were transfected with the respective expression constructs. A
deubiquitinating assay was performed by co-immunoprecipitation with an anti-Flag antibody and immunoblotting using an anti-HA antibody.
doi:10.1371/journal.pone.0037772.g004
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37772Figure 5. Anti-tumor activity of USP17 and SDS3 containing HABMs. A) HeLa cells transfected with empty vector, USP17, USP17DHABM1,
USP17DHABM2, USP17DHABMs, USP17/SDS3-shRNA1, USP17/SDS3-shRNA2 and USP17/Mock-shRNA were plated, in triplicate. After 14 days, the
colonies were stained and numbers were determined by counting colonies from soft agar assay. A mean of triplicate measurements; bars, Standard
deviation, n=3. *, p,0.05. B) The knockdown efficiency of SDS3-shRNA1 and shRNA2 were checked by Western blot analysis in HeLa cells. C) HeLa
cells transfected with empty vector, SDS3, SDS3DHABMs, SDS3/USP17-shRNA1, SDS3/USP17-shRNA2, and SDS3/Mock-shRNA were plated, in
triplicate. A mean of triplicate measurements; bars, Standard deviation, n=3. *, p,0.05. D) The knockdown efficiency of USP17-shRNA1 and shRNA2
were checked by Western blot analysis in HeLa cells. E) HeLa cells transfected with empty vector, USP17, SDS3, USP17/SDS3, and USP17DHABMs/
SDS3DHABMs were plated, in triplicate. Results represent the average number of colonies formed from three individual experiments. A mean of
triplicate measurements; bars, Standard deviation, n=3. *, p,0.05. F) HeLa cells transfected with respective constructs and cell proliferation was
assessed by Cell Counting Kit-8 assay. Mean standard deviation of a triplicate experiment is shown. G) HeLa cells expressing respective constructs
were harvested and stained with annexin V and propidium iodide. The statistical representation of the percentage of apoptosis was recorded. The
results represent the mean (n =3) of a representative experiment. Error bars represent standard error of the mean. *, p,0.05. H) HeLa cells
transfected with respective constructs were checked for HABMs-mediated migratory effect of USP17 or SDS3 by wound healing assays. Percentage of
migration was statistically analyzed from three separate experiments. n =3. *, p,0.05.
doi:10.1371/journal.pone.0037772.g005
Figure 6. HABMs deleted USP17 does not alter SDS3-associated HDAC activity. HeLa cells were transfected with empty vector, SDS3,
USP17/SDS3, USP17DHABM1/SDS3, USP17DHABM2/SDS3, USP17DHABMs/SDS3, USP17-shRNA1/SDS3, USP17-shRNA2/SDS3, and Mock-shRNA/SDS3.
HDAC activity on anti-SDS3 immunoprecipitates was determined by measuring released deacetylase substrate using HDAC assay kit. A mean of
triplicate measurements; bars, Standard deviation, n=3. *, p,0.05.
doi:10.1371/journal.pone.0037772.g006
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HeLa (human ovarian cancer cell line), MCF-7 cells (human
breast adenocarcinoma cell line) and 293T (Human embryonic
kidney cell line) cells were grown in DMEM (GIBCO-BRL
Rockville, MD, USA) supplemented with 10% FBS and 1%
penicillin and streptomycin. Transfections were carried out using
polyethyleneimine (Polysciences, Warrington, PA, USA).
Antibodies
The antibodies used for immunoblotting are polyclonal USP17
antibody (Biomeditech, Seoul, Korea) and anti-SDS3 (ab3740)
(Abcam, Cambridge, UK). Anti-myc (9E10) (sc-40), anti-b-actin
(sc-47778), anti-His-probe (sc-57598) and anti-GST (sc-53909)
antibodies were purchased from Santa Cruz Biotechnology. Anti-
Flag (F3165) antibody was purchased from Sigma Aldrich.
Purification of USP17 and SDS3 Proteins
Bacterial lysate expressing His-tagged SDS3 protein was
purified using HisTrap Kit (Amersham Biosciences). Bacterial
lysate expressing GST-tagged USP17 was purified using Gluta-
thione-Sepharose beads (GE Healthcare). Purified proteins were
subjected to CPC assay.
HA Binding Assay
HA binding assay was carried out according to the protocol as
previously described [13]. Expression constructs such as myc-
USP17, myc-USP17DHABM1, myc-USP17DHABM2, myc-
USP17DHABMs, Flag-SDS3, and Flag-SDS3DHABMs were
transiently transfected into 293T cells along with or without
different concentrations of HA oligosaccharides using polyethyle-
neimine (Polysciences, Warrington, PA, USA). In addition, cell
lysates were incubated with 20 mg of each USP17 peptide (#1:
ATDRRATQGELKRD; #2: EQNKTKPEFNVRKV) or to-
gether in the presence of 50 mg of HA (H5388, Sigma, St. Louis,
MO, USA). The samples were loaded onto 7.5% SDS-PAGE gel
followed by Western blot analysis.
Co-immunoprecipitation for Binding and
Deubiquitination Assays
HeLa cells were transfected with respective constructs for
binding and deubiquitination assays. Co-immunoprecipitation
assay was performed as described previously [11]. The antibodies
used for immunoblotting are anti-myc, anti-Flag and anti-HA
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA).
Soft Agar Clonogenic Assay
HeLa cells were transfected with expression constructs such as
pcDNA3-myc, myc-USP17, myc-USP17DHABMs, Flag-SDS3,
and Flag-SDS3DHABMs. At 48 hrs after transfection, cells were
trypsinized and counted. Soft agar assay was performed as
previously described [36]. The plates were incubated at 37uC
for 10-14 days, and the diameter of tumor colonies were estimated
with a microscope equipped with an ocular scale in the eyepiece.
Colonies with a diameter greater than 0.2 mm were counted.
Cell Counting Assay
100 ml of transfected HeLa cell suspension having 50,000-
100,000 cells/ml was added to 96-well plate. Cell Counting Kit-8
assay was used and the protocol was followed according to the
instructions provided by the company (Dojindo Molecular
Technologies, Rockville, MD, USA). Absorbance was measured
at 450 nm to determine the cell viability in each well.
FACS Analysis
HeLa cells expressing USP17, SDS3 and HABMs deleted
USP17 or SDS3 constructs were harvested and washed with 16
filtered PBS, and the pellet was resuspended in 100 ml of binding
buffer (10 mM Hepes/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM
CaCl2). 5 ml of annexin V-PE (BD Biosciences) and 10 ml
propidium iodide (50 mg/ml, BD Biosciences) were mixed and
added to the samples. FACS analysis was performed as described
previously [13].
Wounding Assay
Migration and proliferation rates were assayed by wounding
assays. HeLa cells transfected with respective constructs were
cultured to near 90% confluence in 100W dish. A line was drawn
with a marker on the bottom of the dish and cell culture medium
was aspirated before wounding. A scratch was made on HeLa
monolayer with a sterile 200 ml pipette tip in a definite array. The
wounded cell layer was washed twice with PBS and incubated in
complete medium and wound closure was documented at 0 h and
16 h. Each analysis was performed in triplicate.
HDAC Assay
The measurement of HDAC activity was performed using a
commercially available kit (BioVision, Mountain View, CA, USA).
The procedure was followed as described previously [11]. The
samples were measured using Tecan Genios Pro (Tecan,
Bubendorf, Switzerland) at 405 nm wavelength.
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